1. Academic Validation
  2. New substituted 4H-chromenes as anticancer agents

New substituted 4H-chromenes as anticancer agents

  • Bioorg Med Chem Lett. 2012 Jul 1;22(13):4458-61. doi: 10.1016/j.bmcl.2012.04.074.
Shivaputra A Patil 1 Jin Wang Xiaochen S Li Jianjun Chen Terreia S Jones Amira Hosni-Ahmed Renukadevi Patil William L Seibel Wei Li Duane D Miller
Affiliations

Affiliation

  • 1 Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN 38163, USA. spatil3@uthsc.edu
Abstract

As a continuation of our efforts to discover and develop small molecules as Anticancer agents, we identified GRI-394837 as an initial hit from similarity search on RGD and its analogs. Based on GRI-394837, we designed and synthesized a focused set of novel chromenes (4a-e) in a single step using microwave method. All five compounds showed activity in the nanomolar range (IC(50): 7.4-640 nM) in two melanoma, three prostate and four glioma Cancer cell lines. The chromene 4e is active against all the cell lines and particularly against the A172 human glioma cell line (IC(50): 7.4 nM). Interestingly, in vitro tubulin polymerization assay shows 4e to be a weak tubulin polymerization inhibitor but it shows very strong cytotoxicity in cellular assays, therefore there must be additional unknown mechanism(s) for the Anticancer activity. Additionally, the strong antiproliferative activity was verified by one of the selected chromene (4a) by the NCI 60 cell line screen. These results strongly suggest that the novel chromenes could be further developed as a potential therapeutic agent for a variety of aggressive cancers.

Figures